Related Experiment Video

Updated: Mar 15, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Drug Development in Non-Oncogene-Addicted Non-Small Cell Lung Cancer

Pedro Cruz1, Cristina Boixareu1, Diogo J Silva1

  • 1Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, London SM2 5GP, UK.

Cancers
|March 14, 2026
PubMed

Insights

Recent advances in non-oncogene-addicted non-small cell lung cancer therapy include new drugs and targets. Despite progress, challenges persist in late-stage trials, prompting innovative drug development strategies.

Area of Science:

  • Oncology
  • Pharmacology
  • Translational Medicine

Background:

  • Non-oncogene-addicted non-small cell lung cancer (NSCLC) therapy has advanced significantly.
  • New molecular targets and biomarkers have led to diverse drug classes like immunotherapies and antibody-drug conjugates.
  • Phase I trials now focus on early efficacy signals alongside toxicity.

Purpose of the Study:

  • To review the current state of drug development in non-oncogene-addicted NSCLC.
  • To highlight recent advances, novel drugs, and emerging targets.
  • To discuss challenges and opportunities in NSCLC drug development.

Main Methods:

  • Review of current literature on NSCLC drug development.
  • Analysis of advances in molecular targeting and biomarker discovery.
  • Examination of challenges in late-stage clinical trial progression.

Main Results:

  • Significant progress in developing targeted therapies and immunotherapies for NSCLC.
  • Identification of new molecular targets and biomarkers.
  • Persistent challenges in phase III trials, particularly in later lines of therapy.

Conclusions:

  • Innovative biological rationales are driving the development of promising new drugs for NSCLC.
  • Addressing late-stage trial failures is crucial for advancing NSCLC treatment.
  • Continued research into novel targets and strategies is essential for improving patient outcomes.
Keywords:
antibody–drug conjugatescarcinomaclinical trialsdrug developmentimmunotherapynon-oncogene-addicted non-small cell lung cancernon-small-cell lung

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

497
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

18.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.3K